Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Chronic Lymphocytic Leukemia (ASH 2023) Basic Listing

Updates in Chronic Lymphocytic Leukemia
From the ASH Annual Meeting & Exposition

Ira L Zackon, MD
Conference Coverage
Evaluating Effects of Racial Disparities on the Treatment of Patients With Chronic Lymphocytic Leukemia
12/12/2023

Fetauring Ira L Zackon, MD

Fetauring Ira L Zackon, MD
At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.
At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.
At the 65th ASH Annual Meeting,...
12/12/2023
Oncology
Jennifer Brown, MD
Conference Coverage
Extended Follow-up of ALPINE Study Confirms Zanubrutinib Yields Progression-Free Survival Benefit vs Ibrutinib for R/R CLL/SLL
12/11/2023

Featuring Jennifer Brown, MD

Featuring Jennifer Brown, MD
At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...
At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...
At the 65th ASH Annual Meeting,...
12/11/2023
Oncology
Adrian Wiestner, MD
Conference Coverage
Analyzing Long-Term Outcomes of Ibrutinib Therapy for Patients With Chronic Lymphocytic Leukemia
12/11/2023

Featuring Adrian Wiestner, MD

Featuring Adrian Wiestner, MD
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, presented long-term follow-up data on a phase 2 study assessing the efficacy, safety, and depth of response of ibrutinib therapy for patients with CLL.
At the 65th ASH Annual Meeting, Adrian Wiestner, MD, presented long-term follow-up data on a phase 2 study assessing the efficacy, safety, and depth of response of ibrutinib therapy for patients with CLL.
At the 65th ASH Annual Meeting,...
12/11/2023
Oncology
Paolo Ghia, MD, PhD
Conference Coverage
Importance of Assessing Minimal Residual Disease for R/R CLL Treatment
12/10/2023

Featuring Paolo Ghia, MD, PhD

Featuring Paolo Ghia, MD, PhD
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, discusses the importance of assessing minimal residual disease when treating patients with relapsed/refractory chronic lymphocytic leukemia, particularly those with high-risk disease.
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, discusses the importance of assessing minimal residual disease when treating patients with relapsed/refractory chronic lymphocytic leukemia, particularly those with high-risk disease.
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Paolo Ghia, MD, PhD
Conference Coverage
Frontline Ibrutinib Plus Venetoclax Treatment Demonstrates Lasting Efficacy for Patients With CLL/SLL
12/10/2023

Featuring Paolo Ghia, MD, PhD

Featuring Paolo Ghia, MD, PhD
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, highlights findings from up to 5 years of follow-up of the CAPTIVATE study, which demonstrates the durable efficacy of ibrutinib plus venetoclax as a first-line treatment among patients...
At the 65th ASH Annual Meeting, Paolo Ghia, MD, PhD, highlights findings from up to 5 years of follow-up of the CAPTIVATE study, which demonstrates the durable efficacy of ibrutinib plus venetoclax as a first-line treatment among patients...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology
Muhammad Bilal Abid, MD
Videos
AlloHSCT Outcomes From Younger Matched Unrelated Donors vs Older Sibling Donors for AML
01/25/2023
Muhammad Bilal Abid, MD, discusses findings from a retrospective cohort study that compared outcomes of patients with AML who underwent alloHSCT with younger matched unrelated donors vs older matched sibling donors, showing a reduced risk of...
Muhammad Bilal Abid, MD, discusses findings from a retrospective cohort study that compared outcomes of patients with AML who underwent alloHSCT with younger matched unrelated donors vs older matched sibling donors, showing a reduced risk of...
Muhammad Bilal Abid, MD,...
01/25/2023
Oncology
Conference Coverage
Tolerability and Efficacy of Azacitidine Plus Venetoclax Maintenance for Patients With AML
12/11/2022

Gina Tomaine

Gina Tomaine
Low-dose azacitidine plus venetoclax demonstrates tolerability and feasibility as maintenance therapy for patients with AML, according to findings from a phase 2 trial with over 13 months of follow-up.
Low-dose azacitidine plus venetoclax demonstrates tolerability and feasibility as maintenance therapy for patients with AML, according to findings from a phase 2 trial with over 13 months of follow-up.
Low-dose azacitidine plus...
12/11/2022
Oncology
Conference Coverage
Venetoclax Plus Azacitidine Sustains OS Benefit for Patients With AML Ineligible for Intensive Chemotherapy
12/11/2022

Gina Tomaine

Gina Tomaine
Long-term follow-up results from the phase 3 VIALE-A trial show sustained OS benefit with venetoclax plus azacitidine vs placebo plus azacitidine for patients with AML ineligible for intensive chemotherapy.
Long-term follow-up results from the phase 3 VIALE-A trial show sustained OS benefit with venetoclax plus azacitidine vs placebo plus azacitidine for patients with AML ineligible for intensive chemotherapy.
Long-term follow-up results from...
12/11/2022
Oncology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement